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Vitiligo is a complex depigmentary disorder characterised 
by the appearance of white patches as a result of the de-
struction of melanocytes in the skin and hair (1). Several 
loci, including AIS1 (1p31) and AISI4 (4q13-q21), have 
been shown to confer susceptibility to the disease (2–3). 
However, the genetic factors involved in vitiligo are yet 
to be clarified. The PRO2268 gene has been mapped, 
by analysis of a cDNA clone (FLB8424) from human 
foetal liver, to the 12q14 chromosomal region, which 
harbours the genes encoding interferon-gamma (IFN-g), 
interleukin (IL)-26 and IL-22. Of note, the IFN-g-IL26-
IL22 gene cluster is associated with autoimmune diseases 
including rheumatoid arthritis and type 1 diabetes (4–6). 
Although the PRO2268 protein (AF119871) has as yet 
unknown functions, a putative role for the PRO2268 
gene is suggested based on our unpublished observation 
(data not shown), by its significantly higher expression 
in the peripheral blood mononuclear cells (PBMCs) of 
vitiligo patients compared to those of control subjects 
(p = 0.036). As part of our ongoing research into the 
impact of susceptibility genetic variants on the risk of 
vitiligo, we selected the rs10784680 single nucleotide 
polymorphism (SNP) within the PRO2268 gene as a 
candidate in our analysis. 
PATIENTS AND METHODS 
A cohort of 194 unaffected controls (106 females, 88 males; 
mean age ± SD 35.49 ± 13.82 years) with no personal or family 
history of vitiligo and 100 vitiligo patients (69 females, 31 ma-
les; mean age ± SD 44.74 ± 15.86 years; mean age at onset ± SD 
28.69 ± 16.24 years) of Caucasian origin were enrolled into a 
case-control study. Diagnoses of vitiligo were made in the De-
partment of Dermatology and Venereology, University of Tartu, 
based on the characteristic loss of skin pigmentation at typical 
locations and Wood’s lamp examinations. The clinical types 
of vitiligo were classified as focal (one or a few macules with 
a nondermatomal distribution; n = 3), acrofacial (affecting the 
distal extremities and face; n = 11), vulgaris (scattered over the 
body; n = 83) and universal (over 90% depigmentation; n = 3). 
In addition, patients were deemed to have active vitiligo if new 
areas of depigmentation had been observed during the previous 
3 months (n = 74) and stable vitiligo if no new depigmentation 
or enlargement of pre-existing depigmented areas had been 
observed for more than 3 months (n = 26). Moreover, vitiligo pa-
tients were categorised with respect to the presence of comorbid 
disorders: 38 had no other disease, 32 one or more autoimmune 
disorders, and 30 other diseases. The Ethics Committee of the 
University of Tartu approved the study and informed consent 
was obtained from all participants.
The rs10784680 SNP was genotyped using the SNPlex Geno-
typing System and analysed using a 3730 DNA Analyzer (App-
lied Biosystems, Foster City, CA) according to manufacturer’s 
instructions. In brief, the assay workflow includes an allele-
specific oligonucleotide reaction, exonuclease purification, 
and PCR amplification. The resulting amplicons are immo-
bilised on streptavidin-coated microtitre plates. ZipChute 
probes are hybridised to complementary ZipCode sequences, 
and non-hybridised ZipChute probes and then washed away. 
Bound ZipChute probes are eluted and analysed by capillary 
electrophoresis (7). 
Data analysis was performed using R software (available from 
www.rproject.org). Logistic regression was used to obtain odds 
ratio (OR) values, as well as Wald’s confidence intervals (CI), 
for alleles and genotypes. A p value of < 0.05 was considered 
statistically significant.
RESULTS AND DISCUSSION
Data analysis revealed that the frequency of the 
rs10784680 G allele was significantly higher in vitiligo 
patients (96%) than in controls (83.5%) (OR = 4.74, 
95% CI 2.22–10.10; p = 0.000055) (Table I). Ac-
cordingly, the rs10784680 GG genotype was signifi-
cantly more frequent in vitiligo patients (92%) than 
in controls (67%) (OR = 5.67, 95% CI 2.59–12.37; 
p = 0.000013). Notably, none of the test subjects car-
ried the rs10784680 AA genotype. However, this 
observation is in accordance with the available data in 
the GenBank database, the rs10784680 AA genotype 
being reportedly absent in Hapmap-CEU, a referent 
population of European ancestry. 
When we analysed the vitiligo patients according to 
their clinical subgroups, no significant differences in 
rs10784680 SNP allele frequency were observed when 
comparing patients on the basis of age at onset (> 20 ye-
ars vs. ≤ 20 years; p = 0.26), sex (male vs. female; p = 1), 
family history (familial vs. sporadic; p = 1) or disease 
activity (active vs. stable vitiligo; p = 0.11) (data not 
shown). Furthermore, no significant differences in allele 
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Table I. Allele and genotype frequencies for the rs10784680  single 





n (%) OR (95% CI) p-value
Allele
A 64 (16.5) 8 (4.0) 1 (ref.) 
G 324 (83.5) 192 (96.0) 4.74 (2.22–10.10) 0.000055 
Total 388 (100.0) 200 (100.0)
Genotype
AG 64 (33.0) 8 (8.0) 1 (ref.)
GG 130 (67.0) 92 (92.0) 5.66 (2.59–12.37) 0.000013
Total 194 (100.0) 100 (100.0)
OR: odds ratio; CI: confidence interval.
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distribution were detected between vitiligo patients with 
autoimmune and other diseases and patients with no 
co-morbidity (p = 0.70 and p = 0.63, respectively) (data 
not shown). In addition, further analysis of our patients 
according to clinical subtype revealed that the frequency 
of the rs10784680 G allele was significant higher in 
the vitiligo vulgaris subgroup than in the control group 
(OR = 4.48, 95% CI 2.01–10.01; p = 0.00024). It should 
be noted that stratifying patients according to clinical 
groups diminished the power to detect associations. 
In conclusion, to our knowledge the present study 
is the first to address the possible influence of the 
PRO2268 gene on the risk of vitiligo. Although the 
function of the PRO2268 protein remains unknown, it 
is of particular interest to note that the PRO2268 gene 
lies adjacent to a region containing the IFN-g-IL26-IL22 
gene cluster, whose gene products play key roles in im-
mune signalling. For this region in particular, extensive 
re-sequencing, further genotyping and targeted functio-
nal studies are essential in order to identify the gene(s) 
that play causal roles in vitiligo. It should be noted that 
we cannot exclude the possibility that new susceptibi-
lity variants of the PRO2268 gene may be discovered, 
or that the PRO2268 gene may play important roles in 
other skin disorders.
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